The biomarkers consortium: On the critical path of drug discovery

Clinical Pharmacology and Therapeutics

Volumn 83, Issue 2, 2008, Pages 361-364

  Altar, C A ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

DEGENERATIVE DISEASE; DIABETES MELLITUS; DISEASE PREDISPOSITION; DRUG COST; DRUG DESIGN; DRUG EFFICACY; DRUG INDUSTRY; DRUG RESEARCH; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HEALTH SERVICE; HUMAN; MEDICAID; MEDICAL PRACTICE; MEDICARE; MOLECULAR IMAGING; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; WORLD HEALTH ORGANIZATION;

ANIMALS; BIOMARKERS, PHARMACOLOGICAL; BIOMEDICAL RESEARCH; COOPERATIVE BEHAVIOR; DRUG DESIGN; HUMANS; INFORMATION DISSEMINATION; INTERDISCIPLINARY COMMUNICATION; INVESTIGATIONAL NEW DRUG APPLICATION; REPRODUCIBILITY OF RESULTS; TECHNOLOGY, PHARMACEUTICAL;

EID: 38349160711     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100471     Document Type: Review

References (20)

1. Insel, T.R. & Lehner, T. A new era in psychiatric genetics? Biol. Psychiatry 61, 1017-1018 (2007).
2. Shaw, L.M., Korecka, M., Clark, C.M., Lee, V.M. & Trojanowski, J.Q. Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. Nat. Rev. Drug Discov. 6, 295-303 (2007).
3. Fuchs, V.R. & Sox Jr. H.C. Physicians' views of the relative importance of thirty medical innovations. Health Aff. (Millwood) 20, 30-42 (2001).
4. Jeerakathil, T. et al. Stroke risk profile predicts white matter hyperintensity volume: the Framingham study. Stroke 35, 1857-1861 (2004).
5. Kelloff, G.J. et al. Progress and promise of FDG-PET imaging for Cancer patient management and oncologic drug development. Clin. Cancer Res. 11, 2785-2808 (2005).
6. Wang, Y., Klunk, W.E., Huang, G.F., Debnath, M.L., Holt, D.P. & Mathis, C.A. Synthesis and evaluation of 2-(3′-iodo-4′-aminophenyl)- 6-hydroxybenzothiazole for in vivo quantitation of amyloid deposits in Alzheimer's disease. J. Mol. Neurosci. 19, 11-16 (2002).
7. Zhang, W., Oya, S., Kung, M.P., Hou, C., Maier, D.L. & Kung, H.F. F-18 Polyethyleneglycol stilbenes as PET imaging agents targeting Aβ aggregates in the brain. Nucl. Med. Biol. 32, 799-809 (2005).
8. Critical Path Opportunities Report and List, http://www.fda.gov/oc/ initiatives/criticalpath/ (2006).
9. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69, 89-95 (2001).
10. Lee, J.W. et al. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm. Res. 23, 312-328 (2006).
11. Daniels, R. Delmar's Manual of Laboratory and Diagnostic Tests (Thompson/ Delmar Learning, Clifton park, NY, 2003).
12. Nicoll, D., McPhee, S.J. & Pignone, M. Common laboratory tests: selection and interpretation. In Pocket Guide to Diagnostic Tests 4th edn. (eds. Nicoll, D., McPhee, S.J. & Pignone, M.) 57 (Lange Medical Books/McGraw-Hill, New York, 2004).
13. Zerhouni, E.A., Sanders, C.A. & von Eschenbach, A.C. The biomarkers consortium: public and private sectors working in partnership to improve the public health. Oncologist 12, 250-252 (2007).
14. Fernández-Real, J.M. et al. Adiponectin is independently associated with glycosylated haemoglobin. Eur. J. Endocrinol. 150, 201-205 (2004).
15. Blüher, M. et al. Total and high-molecular weight adiponectin in relation to metabolic variables at baseline and in response to an exercise treatment program: comparative evaluation of three assays. Diabetes Care 30, 280-285 (2007).
16. Pajvani, U.B. et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J. Biol. Chem. 279, 12152-12162 (2004).
17. Kling, M.A. et al. Sustained low-grade pro-inflammatory state in unmedicated, remitted women with major depressive disorder as evidenced by elevated serum levels of the acute phase proteins C-reactive protein and serum amyloid A. Biol. Psychiatry 62, 309-313 (2007).
18. Fagan, A.M., Roe, C.M., Xiong, C., Mintun, M.A., Morris, J.C. & Holtzman, D.M. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch. Neurol. 64, 343-349 (2007).
19. Hansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K. & Minthon, L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 5, 228-234 (2006).
20. Woodcock, J. The prospects for "personalized medicine" in drug development and drug therapy. Clin. Pharmacol. Ther. 81, 164-169 (2007).